Ignite Creation Date:
2025-12-24 @ 11:52 AM
Ignite Modification Date:
2026-01-02 @ 5:30 AM
Study NCT ID:
NCT04969861
Status:
TERMINATED
Last Update Posted:
2023-01-12
First Post:
2021-07-09
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)
Sponsor:
Nektar Therapeutics
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
20-214-36
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None